1
|
Wang R, Lin Y', Zhang C, Wu H, Jin Q, Guo J, Cao H, Tan D, Wu T. Fine mapping and analysis of a candidate gene controlling Phytophthora blight resistance in cucumber. Plant Biol (Stuttg) 2024. [PMID: 38607927 DOI: 10.1111/plb.13648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/15/2023] [Accepted: 03/25/2024] [Indexed: 04/14/2024]
Abstract
Cucumber blight is a destructive disease. The best way to control this disease is resistance breeding. This study focuses on disease resistance gene mapping and molecular marker development. We used the resistant cucumber, JSH, and susceptible cucumber, B80, as parents to construct F2 populations. Bulked segregant analysis (BSA) combined with specific length amplified fragment sequencing (SLAF-seq) were used, from which we developed cleaved amplified polymorphic sequence (CAPs) markers to map the resistance gene. Resistance in F2 individuals showed a segregation ratio of resistance:susceptibility close to 3:1. The gene in JSH resistant cucumber was mapped to an interval of 9.25 kb, and sequencing results for the three genes in the mapped region revealed three mutations at base sites 225, 302, and 591 in the coding region of Csa5G139130 between JSH and B80, but no mutations in coding regions of Csa5G139140 and Csa5G139150. The mutations caused changes in amino acids 75 and 101 of the protein encoded by Csa5G139130, suggesting that Csa5G139130 is the most likely resistance candidate gene. We developed a molecular marker, CAPs-4, as a closely linked marker for the cucumber blight resistance gene. This is the first report on mapping of a cucumber blight resistance gene and will provideg a useful marker for molecular breeding of cucumber resistance to Phytophthora blight.
Collapse
Affiliation(s)
- R Wang
- Institute of Facility Agriculture, Guangdong Academy of Agricultural Sciences (IFA, GDAAS), Guangzhou, China
| | - Y 'e Lin
- Vegetable Research Institute, Guangdong Academy of Agricultural Sciences/Guangdong Key Laboratory for New Technology Research of Vegetables, Guangzhou, China
| | - C Zhang
- Institute of Facility Agriculture, Guangdong Academy of Agricultural Sciences (IFA, GDAAS), Guangzhou, China
| | - H Wu
- Institute of Facility Agriculture, Guangdong Academy of Agricultural Sciences (IFA, GDAAS), Guangzhou, China
| | - Q Jin
- Vegetable Research Institute, Guangdong Academy of Agricultural Sciences/Guangdong Key Laboratory for New Technology Research of Vegetables, Guangzhou, China
| | - J Guo
- Institute of Facility Agriculture, Guangdong Academy of Agricultural Sciences (IFA, GDAAS), Guangzhou, China
| | - H Cao
- Institute of Facility Agriculture, Guangdong Academy of Agricultural Sciences (IFA, GDAAS), Guangzhou, China
| | - D Tan
- Institute of Facility Agriculture, Guangdong Academy of Agricultural Sciences (IFA, GDAAS), Guangzhou, China
| | - T Wu
- Institute of Facility Agriculture, Guangdong Academy of Agricultural Sciences (IFA, GDAAS), Guangzhou, China
| |
Collapse
|
2
|
Kfoury M, Tan D. Specific issues in the systemic treatment strategy for ovarian clear cell carcinoma. ESMO Open 2024; 9:102568. [PMID: 38387110 PMCID: PMC10899029 DOI: 10.1016/j.esmoop.2024.102568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2024] Open
Affiliation(s)
- M Kfoury
- Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France.
| | - D Tan
- Department of Medical Oncology, National University Cancer Institute, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| |
Collapse
|
3
|
Qin J, Zhang C, Zhao Y, Tan D, Wu P, Shui X, Qin W, Ge X, Shi C. Small Mitochondria-Targeting Fluorophore with Multifunctional Therapeutic Activities against Prostate Cancer via the HIF1α/OATPs Pathway. Mol Pharm 2023; 20:6226-6236. [PMID: 37955533 DOI: 10.1021/acs.molpharmaceut.3c00621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2023]
Abstract
Prostate cancer (PCa) is considered to be the most prevalent malignancy in males worldwide. Abiraterone is a 17α-hydroxylase/C17, 20-lyase (CYP17) inhibitor that has been approved for use in patients with prostate cancer. However, several negative aspects, such as drug resistance, toxicity, and lack of real-time monitoring of treatment responses, could appear with long-term use. Therefore, the development of anticancer agents with specific targeting to avoid side effects is imperative. Here, we used MHI-148, a type of heptamethine cyanine (HC) near-infrared fluorescence dye (NIRF), as a prototype structure to synthesize two theranostic agents, Abi-DZ-1 and Abi-783. The new compound Abi-DZ-1 retained the excellent photophysical characteristics and NIRF imaging property of MHI-148, and it could preferentially accumulate in prostate cancer cells but not in normal prostate epithelial cells via the HIF1α/organic anion-transporting polypeptides axis. NIRF imaging using Abi-DZ-1 selectively identified tumors in mice bearing PCa xenografts. Moreover, Abi-DZ-1 treatment significantly retarded the tumor growth in both a cell-derived xenograft model and a patient-derived tumor xenograft model. This finding demonstrated that Abi-DZ-1 may hold promise as a potential multifunctional theranostic agent for future tumor-targeted imaging and precision therapy. Constructing theranostic agents using the NIRF dye platform holds great promise in accurate therapy and intraoperative navigation.
Collapse
Affiliation(s)
- Jing Qin
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
| | - Caiqin Zhang
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
| | - Yong Zhao
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
| | - Dengxu Tan
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710069, China
| | - Pengpeng Wu
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
| | - Xue Shui
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
| | - Weijun Qin
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710069, China
| | - Xu Ge
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
| | - Changhong Shi
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
| |
Collapse
|
4
|
Gong M, Meng H, Tan D, Li P, Qin J, An Q, Shi C, An J. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy. Animal Model Exp Med 2023; 6:409-418. [PMID: 37890865 PMCID: PMC10614126 DOI: 10.1002/ame2.12352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 09/20/2023] [Indexed: 10/29/2023] Open
Abstract
BACKGROUND Patients with pancreatic ductal adenocarcinoma (PDAC) who undergo surgical resection and receive effective chemotherapy have the best chance for long-term survival. Unfortunately, because of the heterogeneity of pancreatic cancer, it is difficult to find a personalized treatment strategy for patients. Organoids are ideal preclinical models for personalized medicine. Therefore, we explore the cultivation conditions and construction methods of PDAC organoid models to screen the individualized therapy strategy. METHODS Fresh PDAC tissues from surgical resection were collected and digested with digestive enzymes; then the tumor cells were embedded in Matrigel with a suitable medium to establish the PDAC organoid models. The genetic stability of the organoids was analyzed using whole exon sequencing; hematoxylin and eosin staining and immunohistochemistry of organoids were performed to analyze their consistency with the pathological morphology of the patient's tumor tissue; After 2 days of organoid culture, we selected four commonly used clinical chemotherapy drugs for single or combined treatment to analyze drug sensitivity. RESULTS Two cases of PDAC organoid models were successfully established, and the results of their pathological characteristics and exome sequencing were consistent with those of the patient's tumor tissue. Both PDAC organoids showed more sensitivity to gemcitabine and cisplatin, and the combined treatment was more effective than monotherapy. CONCLUSION Both organoids better retained the pathological characteristics, genomic stability, and heterogeneity with the original tumor. Individual PDAC organoids exhibited different sensitivities to the same drugs. Thus, this study provided ideal experimental models for screening individualized therapy strategy for patients with PDAC.
Collapse
Affiliation(s)
- Miaomiao Gong
- Division of Cancer Biology, Laboratory Animal CenterFourth Military Medical UniversityXi'anChina
- School of Basic Medical SciencesMedical College of Yan'an UniversityYananChina
| | - Han Meng
- Division of Cancer Biology, Laboratory Animal CenterFourth Military Medical UniversityXi'anChina
| | - Dengxu Tan
- Division of Cancer Biology, Laboratory Animal CenterFourth Military Medical UniversityXi'anChina
| | - Peng Li
- Division of Cancer Biology, Laboratory Animal CenterFourth Military Medical UniversityXi'anChina
- Animal Experiment CenterGuangzhou University of Chinese MedicineGuangzhouChina
| | - Jing Qin
- Division of Cancer Biology, Laboratory Animal CenterFourth Military Medical UniversityXi'anChina
| | - Qingling An
- Division of Cancer Biology, Laboratory Animal CenterFourth Military Medical UniversityXi'anChina
| | - Changhong Shi
- Division of Cancer Biology, Laboratory Animal CenterFourth Military Medical UniversityXi'anChina
| | - Jiaze An
- Department of Hepatobiliary and Pancreaticosplenic Surgery, Xijing HospitalFourth Military Medical UniversityXi'anChina
| |
Collapse
|
5
|
Tan D, Mohd Nasir NF, Abdul Manan H, Yahya N. Prediction of toxicity outcomes following radiotherapy using deep learning-based models: A systematic review. Cancer Radiother 2023; 27:398-406. [PMID: 37482464 DOI: 10.1016/j.canrad.2023.05.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 05/16/2023] [Accepted: 05/19/2023] [Indexed: 07/25/2023]
Abstract
PURPOSE This study aims to perform a comprehensive systematic review of deep learning (DL) models in predicting RT-induced toxicity. MATERIALS AND METHODS A literature review was performed following the PRISMA guidelines. Systematic searches were performed in PubMed, Scopus, Cochrane and Embase databases from the earliest record up to September 2022. Related studies on deep learning models for radiotherapy toxicity prediction were selected based on predefined PICOS criteria. RESULTS Fourteen studies of radiotherapy-treated patients on different types of cancer [prostate (n=2), HNC (n=4), liver (n=2), lung (n=4), cervical (n=1), and oesophagus (n=1)] were eligible for inclusion in the systematic review. Information regarding patient characteristics and model development was summarized. Several approaches, such as ensemble learning, data augmentation, and transfer learning, that were utilized by selected studies were discussed. CONCLUSION Deep learning techniques are able to produce a consistent performance for toxicity prediction. Future research using large and diverse datasets and standardization of the study methodologies are required to improve the consistency of the research output.
Collapse
Affiliation(s)
- D Tan
- Centre of Diagnostic, Therapeutic and Investigative Sciences (CODTIS). Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Aziz, Kuala Lumpur 50300 Malaysia
| | - N F Mohd Nasir
- Centre of Diagnostic, Therapeutic and Investigative Sciences (CODTIS). Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Aziz, Kuala Lumpur 50300 Malaysia
| | - H Abdul Manan
- Functional Image Processing Laboratory, Department of Radiology, Universiti Kebangsaan Malaysia Medical Centre, Cheras, Kuala Lumpur 56000, Malaysia
| | - N Yahya
- Centre of Diagnostic, Therapeutic and Investigative Sciences (CODTIS). Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Aziz, Kuala Lumpur 50300 Malaysia.
| |
Collapse
|
6
|
Chew N, Ng CH, Tan D, Kong G, Lin CX, Chin YH, Foo R, Chan M, Muthiah M. Global burden of metabolic diseases: data from Global Burden of Disease 2000-2019. A cosortium of metabolic disease. Eur Heart J 2023. [DOI: 10.1093/eurheartj/ehac779.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
The growing prevalence of metabolic diseases is a major concern. We sought to examine the global trends and mortality of metabolic diseases using estimates from the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2019.
Methods
Global estimates of prevalence, deaths, and disability-adjusted life year (DALYs) from 2000-2019 were examined for metabolic diseases (type 2 diabetes mellitus [T2DM], hypertension, and nonalcoholic fatty liver disease [NAFLD]). For metabolic risk factors (hyperlipidemia and obesity), estimates were limited to mortality and DALYs. Death rates was compared across sex, World Health Organisation regions and Socio-demographic Index (SDI) quintiles. Age-standardised prevalence and death rates were presented per 100,000 population with 95% uncertainty intervals (UI).
Findings
From 2000 to 2019, prevalence rates increased for all metabolic diseases, with the most pronounced increase in high SDI countries. In 2019, the mean (95%UI) age-standardised prevalence per 100,000 population was estimated to be 15,023 (13,493-16,764) for NAFLD, 5,283 (4,864–5,720) for T2DM and 234 (171-313) for hypertension. The highest age-standardised death rates were observed in obesity (62·59 [39·92-89·13]; males, 66·55 [39·76-97·21]; females. 58·14 [38·53-81·39]), followed by hyperlipidemia (56·51 [41·83-73·62]; males, 67·33 [50·78-86·43]; females, 46·50 [32·70-62·38]), T2DM (18·49 [17·18-19·66], males, 67·33 [50·78-86·43]; females, 46·50 [32·70-62·38]), hypertension (15·16 [11·20-16·75]; males, 14·95 [10·32-16·75]; females, 15·05 [11·51-17·09]) and NAFLD (2·09 [1·61-2·60]; males, 2·38 [1·82-3·02]; females, 1·82 [1·41-2·27]). Mortality rates decreased over time in hyperlipidemia (-154%), hypertension (-52%) and NAFLD (-52%), but not in T2DM and obesity. The highest mortality for metabolic diseases was found in Eastern Mediterranean, and low to low-middle SDI countries.
Conclusion
The global prevalence of metabolic diseases has risen over the past two decades regardless of SDI. Attention is needed to address the unchanging mortality rates attributed to metabolic disease and the regional, socioeconomic, and sex disparities in mortality from metabolic disease.
Collapse
Affiliation(s)
- N Chew
- National University Health System , Singapore , Singapore
| | - C H Ng
- National University Health System , Singapore , Singapore
| | - D Tan
- National University Health System , Singapore , Singapore
| | - G Kong
- National University Heart Centre , Singapore , Singapore
| | - C X Lin
- National University Heart Centre , Singapore , Singapore
| | - Y H Chin
- National University Heart Centre , Singapore , Singapore
| | - R Foo
- National University Heart Centre , Singapore , Singapore
| | - M Chan
- National University Heart Centre , Singapore , Singapore
| | - M Muthiah
- National University Health System , Singapore , Singapore
| |
Collapse
|
7
|
Tan D, An J, Gong M, Wang H, Li H, Meng H, Zhang C, Zhao Y, Ge X, Shi C. Screening of an individualized treatment strategy for an advanced gallbladder cancer using patient-derived tumor xenograft and organoid models. Front Oncol 2022; 12:1043479. [PMID: 36591461 PMCID: PMC9795198 DOI: 10.3389/fonc.2022.1043479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 11/28/2022] [Indexed: 12/15/2022] Open
Abstract
Gallbladder cancer is a highly aggressive malignancy with poor sensitivity to postoperative radiotherapy or chemotherapy; therefore, the development of individualized treatment strategies is paramount to improve patient outcomes. Both patient-derived tumor xenograft (PDX) and patient-derived tumor organoid (PDO) models derived from surgical specimens can better preserve the biological characteristics and heterogeneity of individual original tumors, display a unique advantage for individualized therapy and predicting clinical outcomes. In this study, PDX and PDO models of advanced gallbladder cancer were established, and the consistency of biological characteristics between them and primary patient samples was confirmed using pathological analysis and RNA-sequencing. Additionally, we tested the efficacy of chemotherapeutic drugs, targeted drugs, and immune checkpoint inhibitors using these two models. The results demonstrated that gemcitabine combined with cisplatin induced significant therapeutic effects. Furthermore, treatment with immune checkpoint inhibitors elicited promising responses in both the humanized mice and PDO immune models. Based on these results, gemcitabine combined with cisplatin was used for basic treatment, and immune checkpoint inhibitors were applied as a complementary intervention for gallbladder cancer. The patient responded well to treatment and exhibited a clearance of tumor foci. Our findings indicate that the combined use of PDO and PDX models can guide the clinical treatment course for gallbladder cancer patients to achieve individualized and effective treatment.
Collapse
Affiliation(s)
- Dengxu Tan
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi’an, Shaanxi, China,Gansu Provincial Laboratory Animal Industry Technology Center, Gansu University of Chinese medicine, Lanzhou, Gansu, China
| | - Jiaze An
- Department of Hepatobiliary and Pancreaticosplenic Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, China
| | - Miaomiao Gong
- School of Basic Medical Sciences, Medical College of Yan’an University, Yan’an, China
| | - Huihui Wang
- Gansu Provincial Laboratory Animal Industry Technology Center, Gansu University of Chinese medicine, Lanzhou, Gansu, China
| | - Han Li
- Group 4, School of Basic Medicine, Air Force Military Medical University, Xi’an, Shaanxi, China
| | - Han Meng
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi’an, Shaanxi, China
| | - Caiqin Zhang
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi’an, Shaanxi, China
| | - Yong Zhao
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi’an, Shaanxi, China
| | - Xu Ge
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi’an, Shaanxi, China,*Correspondence: Changhong Shi, ; Xu Ge,
| | - Changhong Shi
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi’an, Shaanxi, China,*Correspondence: Changhong Shi, ; Xu Ge,
| |
Collapse
|
8
|
Chew NWS, Ng CH, Kong G, Tan D, Lim WH, Kofidis T, Yip J, Loh PH, Chan KH, Low A, Lee CH, Yeo TC, Tan HC, Chan MY. Reconstructed meta-analysis of percutaneous coronary intervention versus coronary artery bypass grafting for left main disease. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Randomized controlled trials (RCTs) comparing percutaneous coronary intervention (PCI) with drug-eluting stents and coronary artery bypass grafting (CABG) for patients with left main coronary artery disease (LMCAD) have reported conflicting results.
Objectives
We performed a systematic review from inception to 23 May 2021 and one-stage reconstructed individual-patient data meta-analysis (IPDMA) that included 10-year mortality outcomes.
Methods
The primary outcome was 10-year all-cause mortality. Secondary outcomes included myocardial infarction (MI), stroke and unplanned revascularization at 5 years. We did IPDMA using published Kaplan-Meier curves to provide individual data points in coordinates and numbers at risk were used to increase the calibration accuracy of the reconstructed data. Shared frailty model or, when proportionality assumptions were not met, a restricted mean survival time model were fitted to compare outcomes between treatment groups.
Results
Of 583 articles retrieved, 5 RCTs were included. A total of 4595 patients from these 5 RCTs were randomly assigned to PCI (N=2297) or CABG (N=2298). The cumulative 10-year all-cause mortality after PCI and CABG was 12.0% versus 10.6% respectively (HR 1.093, 95% CI: 0.925–1.292; p=0.296). PCI conferred similar time-to-MI (RMST ratio 1.006, 95% CI: 0.992–1.021, p=0.391) and stroke (RMST ratio 1.005, 95% CI: 0.998–1.013, p=0.133) at 5 years. Unplanned revascularization was more frequent following PCI compared with CABG (HR 1.807, 95% CI: 1.524–2.144, p<0.001) at 5 years.
Conclusion
This meta-analysis using reconstructed participant-level time-to-event data showed no statistically significant difference in cumulative 10-year all-cause mortality between PCI versus CABG in the treatment of LMCAD.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- N W S Chew
- National University Heart Centre , Singapore , Singapore
| | - C H Ng
- National University of Singapore , Singapore , Singapore
| | - G Kong
- National University of Singapore , Singapore , Singapore
| | - D Tan
- National University of Singapore , Singapore , Singapore
| | - W H Lim
- National University of Singapore , Singapore , Singapore
| | - T Kofidis
- National University Heart Centre , Singapore , Singapore
| | - J Yip
- National University Heart Centre , Singapore , Singapore
| | - P H Loh
- National University Heart Centre , Singapore , Singapore
| | - K H Chan
- National University Heart Centre , Singapore , Singapore
| | - A Low
- National University Heart Centre , Singapore , Singapore
| | - C H Lee
- National University Heart Centre , Singapore , Singapore
| | - T C Yeo
- National University Heart Centre , Singapore , Singapore
| | - H C Tan
- National University Heart Centre , Singapore , Singapore
| | - M Y Chan
- National University Heart Centre , Singapore , Singapore
| |
Collapse
|
9
|
Li S, Liu S, Wu Y, Liu Y, Tan D, Fan Y, Wei C, Xiong H. VP.21 Baseline nutrition investigation in a Chinese cohort of pediatric patients with spinal muscular atrophy. Neuromuscul Disord 2022. [DOI: 10.1016/j.nmd.2022.07.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
10
|
Tan D, Zhang H, Xiong H. VP.77 Muscle transcriptomic study of a novel LAMA2-related congenital muscular dystrophy mouse model. Neuromuscul Disord 2022. [DOI: 10.1016/j.nmd.2022.07.339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
11
|
Huang X, Yang H, Tan D, Ge L, Fan Y, Chang X, Yang Z, Xiong H. VP.78 Clinical and genetic study of LAMA2-related muscular dystrophy patients with seizures. Neuromuscul Disord 2022. [DOI: 10.1016/j.nmd.2022.07.340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
12
|
Geng P, Ling B, Yang Y, Walline JH, Song Y, Lu M, Wang H, Zhu Q, Tan D, Xu J. THIRD bedside ultrasound protocol for rapid diagnosis of undifferentiated shock: a prospective observational study. Hong Kong Med J 2022; 28:383-391. [PMID: 36171145 DOI: 10.12809/hkmj219648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023] Open
Abstract
INTRODUCTION It is clinically challenging to differentiate the pathophysiological types of shock in emergency situations. Here, we evaluated the ability of a novel bedside ultrasound protocol (Tamponade/tension pneumothorax, Heart, Inferior vena cava, Respiratory system, Deep venous thrombosis/aorta dissection [THIRD]) to predict types of shock in the emergency department. METHODS An emergency physician performed the THIRD protocol on all patients with shock who were admitted to the emergency department. All patients were closely followed to determine their final clinical diagnoses. The kappa index, sensitivity, specificity, positive predictive value, and negative predictive value were calculated for the initial diagnostic impression provided by the THIRD protocol, compared with each patient's final diagnosis. RESULTS In total, 112 patients were enrolled in this study. The kappa index between initial impression and final diagnosis was 0.81 (95% confidence interval=0.73-0.89; P<0.001). For hypovolaemic, cardiogenic, distributive, and obstructive types of shock, the sensitivities of the THIRD protocol were 100%, 100%, 93%, and 100%, respectively; the sensitivity for a 'mixed' shock aetiology was 86%. The negative predictive value of the THIRD protocol for all five types of shock was ≥96%. CONCLUSION Initial diagnostic judgements determined using the THIRD protocol showed favourable agreement with the final diagnosis in patients who presented with undifferentiated shock. The THIRD protocol has great potential for use as a bedside approach that can guide the rapid management of undifferentiated shock in emergency settings, particularly for patients with obstructive, hypovolaemic, or cardiogenic shock.
Collapse
Affiliation(s)
- P Geng
- Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China
| | - B Ling
- Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China
| | - Y Yang
- Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China
| | - J H Walline
- Accident and Emergency Medicine Academic Unit, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
| | - Y Song
- Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China
| | - M Lu
- Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China
| | - H Wang
- Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China
| | - Q Zhu
- Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China
| | - D Tan
- Department of Emergency Medicine, Clinical Medical College of Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China
| | - J Xu
- Department of Emergency Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
| |
Collapse
|
13
|
Sukhadia B, Tan D, Oh Y, Chae Y. EP08.02-023 Differentiation Syndrome in a Patient with Non-Small-Cell Lung Cancer Harboring IDH2 Mutation Treated with Enasidenib. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
14
|
Ang T, Tan D, Goh B, Ng WT, Tan BBC, See B. Functional assessment of military aircrew applicants in a hypobaric chamber. Occup Med (Lond) 2022; 72:452-455. [DOI: 10.1093/occmed/kqac059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Aircrew are exposed to environmental pressure changes. In the Republic of Singapore Air Force (RSAF), applicants assessed to be at intermediate risk of otic barotrauma undergo a hypobaric chamber assessment [“trial of chamber” (TOC)] to functionally evaluate their suitability for military aircrew vocations.
Aims
To identify factors associated with TOC failure among applicants with otorhinolaryngological conditions.
Methods
All applicants to RSAF aircrew vocations who were assessed to be at intermediate risk of otic barotrauma over a 3-yr period were identified using the RSAF Aeromedical Centre’s electronic database. Their medical records, as well as the TOC assessment records of the subset of applicants who underwent TOC, were reviewed for demographic data, clinical findings, and TOC outcomes.
Results
Of the 483 identified applicants, 374 (77%) had abnormal otoscopic findings, 103 (21%) had rhinitis symptoms, and 6 (1%) had previous ENT surgery. 123 (25%) underwent TOC, of which 20 (16%) failed. Holding other predictor variables constant, the odds of TOC failure increased by 0.79 per unit decrease in BMI (95% CI 0.63–0.99), and the odds of TOC failure increased by 0.93 per kg decrease in body weight (95% CI 0.87–1.00). An abnormal tympanogram was not a statistically significant predictor of TOC failure (OR 1.96, 95% CI 0.59–6.42). Of the 47 applicants who passed TOC and were eventually recruited, none subsequently developed otic barotrauma (mean follow-up, 3.3 yr ± 1.5 yr).
Conclusions
Applicants with lower weight and BMI are more likely to develop otic barotrauma with environmental pressure change. Tympanometry cannot be reliably used to identify applicants who would more likely pass TOC.
Collapse
Affiliation(s)
- T Ang
- Aeromedical Centre, Republic of Singapore Air Force Medical Service , Singapore 539945
| | - D Tan
- Aeromedical Centre, Republic of Singapore Air Force Medical Service , Singapore 539945
| | - B Goh
- Aeromedical Centre, Republic of Singapore Air Force Medical Service , Singapore 539945
| | - W T Ng
- Saw Swee Hock School of Public Health, National University of Singapore , Singapore 117549
| | - B B C Tan
- Aeromedical Centre, Republic of Singapore Air Force Medical Service , Singapore 539945
| | - B See
- Aeromedical Centre, Republic of Singapore Air Force Medical Service , Singapore 539945
- Saw Swee Hock School of Public Health, National University of Singapore , Singapore 117549
| |
Collapse
|
15
|
Zhang H, Wu P, Guo C, Zhang C, Zhao Y, Tan D, An J, Shi C. Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine. Biochem Biophys Rep 2022; 31:101291. [PMID: 35669987 PMCID: PMC9166468 DOI: 10.1016/j.bbrep.2022.101291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 04/29/2022] [Accepted: 05/27/2022] [Indexed: 11/29/2022] Open
Abstract
Owing to the high heterogeneity of pancreatic cancer, patient-derived xenografts (PDX) can compensate for the defects of cell line-derived xenografts (CDX) and also better preserve the heterogeneity and tumor microenvironment of primary tumors. Further, gemcitabine, which is used for the treatment of various cancers, is prone to tumor drug resistance, and this limits its sustained efficacy. Therefore, in this study, our objective was to screen appropriate individual therapeutic drugs for pancreatic cancer. To this end, we established pancreatic cancer PDX models from different patients and screened gemcitabine sensitivity regulatory molecules via high-throughput transcriptome sequencing and bioinformatics analysis. Based on the results obtained, gemcitabine was identified as the most suitable chemotherapeutic drug in a variety of PDX models. Additionally, our results indicated that Lipocalin 2 (LCN 2) may play an important role in the sensitivity of pancreatic cancer to gemcitabine treatment. Thus, the study provides a new potential intervention target for the treatment of pancreatic cancer in clinical practice. PDX model plays an important role in the screening of chemotherapeutic agents for pancreatic cancer. Gemcitabine is the most suitable chemotherapeutic drug in a variety of PDX models of pancreatic cancer. Lcn2 may be involved in the sensitivity of gemcitabine in the treatment of pancreatic cancer and the change of Lipocalin 2 levels determines the gemcitabine therapeutic output.
Collapse
Affiliation(s)
- He Zhang
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, 710032, China
| | - Pengpeng Wu
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, 710032, China
| | - Chenbo Guo
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, 710032, China.,Gansu University of Traditional Chinese Medicine, Lanzhou, 730030, China
| | - Caiqin Zhang
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, 710032, China
| | - Yong Zhao
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, 710032, China
| | - Dengxu Tan
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, 710032, China
| | - Jiaze An
- Department of Hepatobiliary and Pancreaticosplenic Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710069, China
| | - Changhong Shi
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, 710032, China
| |
Collapse
|
16
|
Ward J, Gill S, Armstrong K, Fogarty T, Tan D, Scott A, Yahya A, Dhaliwal S, Jacques A, Tang C. PO-1384 Simethicone use to Reduce Rectal Variability During Prostate Cancer Radiotherapy, a Randomised Trial. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03348-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
17
|
Asokkumar R, Seow I, Chin Hong L, Chang J, Tan D, Salazar E. Rostered routine testing for severe acute respiratory coronavirus virus 2 infection among healthcare workers: Do we detect more? J Gastroenterol Hepatol 2022; 37:404-405. [PMID: 34694645 PMCID: PMC8656364 DOI: 10.1111/jgh.15720] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Accepted: 10/20/2021] [Indexed: 12/13/2022]
Affiliation(s)
- R Asokkumar
- Department of Gastroenterology and HepatologySingapore General HospitalSingapore,Duke‐NUS Graduate Medical SchoolSingapore
| | - I Seow
- Department of Colorectal SurgerySingapore General HospitalSingapore,Duke‐NUS Graduate Medical SchoolSingapore
| | - L Chin Hong
- Department of Upper Gastrointestinal and Bariatric SurgerySingapore General HospitalSingapore,Duke‐NUS Graduate Medical SchoolSingapore
| | - J Chang
- Department of Gastroenterology and HepatologySingapore General HospitalSingapore,Duke‐NUS Graduate Medical SchoolSingapore
| | - D Tan
- Department of Gastroenterology and HepatologySingapore General HospitalSingapore,Duke‐NUS Graduate Medical SchoolSingapore
| | - E Salazar
- Department of Gastroenterology and HepatologySingapore General HospitalSingapore,Duke‐NUS Graduate Medical SchoolSingapore
| |
Collapse
|
18
|
Tan A, Lai G, Saw S, Chua K, Takano A, Ong B, Koh T, Jain A, Tan W, Ng Q, Kanesvaran R, Rajasekaran T, Kalshnikova E, Shchegrova S, H. -Ta, Lin J, Renner D, Sethi H, Zimmermann B, Aleshin A, Lim W, Tan E, Skanderup A, Ang M, Tan D. MA07.06 Circulating Tumor DNA for Monitoring Minimal Residual Disease and Early Detection of Recurrence in Early Stage Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Dooms C, Nadal E, Raskin J, Demedts I, Mazieres J, Wislez M, Abdul S, Mun T, Wang C, Viteri S, Le X, How S, Tan D, Takeda M, Veillon R, Karachaliou N, Ellers-Lenz B, Smit E, Wu Y. P47.09 Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Drilon A, Lin J, Lassen U, Leyvraz S, Liu Y, Patel J, Rosen L, Solomon B, Norenberg R, Dima L, Brega N, Shen L, Moreno V, Kummar S, Tan D. P53.02 Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Li F, Zhang F, Tan D, Ye J, Tong W. Robotic transanal total mesorectal excision combined with intersphincteric resection for ultra-low rectal cancer. Tech Coloproctol 2021; 25:1335-1336. [PMID: 34236533 DOI: 10.1007/s10151-021-02494-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Accepted: 06/23/2021] [Indexed: 11/24/2022]
Affiliation(s)
- F Li
- Department of General Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China
| | - F Zhang
- Department of General Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China
| | - D Tan
- Department of General Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China
| | - J Ye
- Department of General Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China.,Department of General Surgery, The People's Hospital of Shapingba District, Chongqing, China
| | - W Tong
- Department of General Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China.
| |
Collapse
|
22
|
De Mel S, Goh J, Rashid MBMA, Zhang XY, Jaynes P, Liu X, Poon L, Chan E, Lee J, Chee YL, Koh LP, Tan LK, Soh TG, Yuen YC, Loi H, Ng S, Goh X, Tan D, Cheah DMZ, Pang WL, Huang D, Chan JY, Somasundaram N, Tang T, Lim ST, Ong CK, Chng W, Chow EK, Jeyasekharan AD. CLINICAL APPLICATION OF AN EX‐VIVO PLATFORM TO GUIDE THE CHOICE OF DRUG COMBINATIONS IN RELAPSED/REFRACTORY LYMPHOMA; A PROSPECTIVE STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.147_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- S De Mel
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - J Goh
- National University of Singapore Cancer Science Institute of Singapore Singapore Singapore
| | | | - X. Y Zhang
- National University of Singapore Cancer Science Institute of Singapore Singapore Singapore
| | - P Jaynes
- National University of Singapore Cancer Science Institute of Singapore Singapore Singapore
| | - X Liu
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - L Poon
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - E Chan
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - J Lee
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - Y. L Chee
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - L. P Koh
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - L. K Tan
- National University Hospital Department of Laboratory Medicine Singapore Singapore
| | - T. G Soh
- National University Hospital Department of Laboratory Medicine Singapore Singapore
| | - Y. C Yuen
- National University Health System Department of Pharmacy Singapore Singapore
| | - Hoi‐Y Loi
- National University Hospital Singapore Department of Diagnostic Imaging Singapore Singapore
| | - Siok‐B Ng
- National University of Singapore Department of Pathology Yong Loo Lin School of Medicine Singapore Singapore
| | - X Goh
- National University Hospital, Department of Otorhinolaryngology Singapore Singapore
| | - D Tan
- Mt Elizabeth Hospital, Dr Daryl Tan Clinic for Lymphoma, Myeloma and Blood Disorders Singapore Singapore
| | - D. M. Z Cheah
- National Cancer Centre Singapore Lymphoma Genomic Translational Research Laboratory Division of Cellular and Molecular Research Singapore Singapore
| | - W. L Pang
- National Cancer Centre Singapore Lymphoma Genomic Translational Research Laboratory Division of Cellular and Molecular Research Singapore Singapore
| | - D Huang
- National Cancer Centre Singapore Lymphoma Genomic Translational Research Laboratory Division of Cellular and Molecular Research Singapore Singapore
| | - J. Y Chan
- National Cancer Centre Singapore Division of Medical Oncology Singapore Singapore
| | - N Somasundaram
- National Cancer Centre Singapore Division of Medical Oncology Singapore Singapore
| | - T Tang
- National Cancer Centre Singapore Division of Medical Oncology Singapore Singapore
| | - S. T Lim
- National Cancer Centre Singapore Division of Medical Oncology Singapore Singapore
| | - C. K Ong
- National Cancer Centre Singapore Division of Cellular and Molecular Research Singapore Singapore
| | - W.‐J Chng
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| | - E. K Chow
- National University of Singapore Cancer Science Institute of Singapore Singapore Singapore
| | - A. D Jeyasekharan
- National University Health System Department of Haematology‐Oncology National University Cancer Institute, Singapore Singapore Singapore
| |
Collapse
|
23
|
Lim K, Tan G, Tan D, Tan A, Chen E. P37.18 Lung NSCLC Molecular Diagnostic Comparison Between NGS and Multiplex PCR Assays. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
24
|
Tan W, Chua B, Yin D, Tan S, Tan D, Ang M, Kanesvaran R, Jain A, Rajasekaran T, Lai G, Toh C, Tan E, Ng Q, Lim W. P76.46 First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
25
|
Yuan J, Lim E, Ma S, Chua K, Lee Y, Lim M, Yeo X, Phua C, Takano A, Aung Z, Lim K, Tan E, Tan D, Chew G, Tam W. P69.05 Molecular and Cellular Heterogeneity Underpin Treatment Response Across a Spectrum of EGFR-Mutant Non-Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
26
|
Tan A, Lai G, Tan G, Seet A, Takano A, Alvarez J, Skanderup A, Tan W, Ang M, Kanesvaran R, Ng Q, Jain A, Rajasekaran T, Lim W, Tan E, Lim K, Tan D. FP14.13 Molecular Characterisation and Clinical Outcomes in RET Rearranged Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
27
|
Tan A, Ong B, Koh T, Chen J, Oo H, Lai G, Tan W, Ang M, Kanesvaran R, Ng Q, Jain A, Rajasekaran T, Zhai W, Skanderup A, Lim K, Tan E, Lim W, Tan D, Takano A. P38.03 Immunohistochemical, Histologic and Genomic Characterisation of Early Stage Pulmonary Invasive Mucinous Adenocarcinoma. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
28
|
Felip E, Minotti V, Tan D, Wolf J, Mark M, Boyer M, Hughes B, Bearz A, Moro-Sibilot D, Le X, Vazquez J, Massuti B, Liu N, Hao L, Cheng Y, Tiedt R, Cobo M. P76.03 Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non–Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
29
|
Ma J, Tan S, Yin D, Tran A, Tan D, Ang M, Takano A, Lim K, Kanesvaran R, Jain A, Rajasekaran T, Tan E, Lim D, Ng Q, Tan W. P76.88 Real-World Data of Osimertinib in Patients with Metastatic EGFRm+ NSCLC who Progressed on First-Line EGFR TKIs. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Loong H, Goto K, Park K, Ohe Y, Nishio M, Cho B, Kim Y, French P, Soldatenkova V, Tan D. FP14.10 Efficacy and Safety of Selpercatinib (LOXO-292) in East Asian Patients with RET Fusion-Positive NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.153] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
31
|
Lai G, Alvarez J, Yeo J, Sim N, Tan A, Zhou S, Suteja L, Lim T, Rohatgi N, Yeong J, Takano A, Lim K, Gogna A, Too C, Zhuang K, Jain A, Tan W, Kanesvaran R, Ng Q, Ang M, Rajasekaran T, Wang L, Toh C, Lim W, Tam W, Ginhoux F, Tan S, Skanderup A, Tan D, Tan E. OA01.06 Randomised Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR Mutant NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.274] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Saw S, Lai G, Zhou S, Chen J, Ang M, Chua K, Kanesvaran R, Ng Q, Jain A, Tan W, Rajasekaran T, Lim D, Fong K, Takano A, Cheng X, Lim K, Koh T, Ong B, Tan E, Skanderup A, Tan D. OA06.05 Molecular and Clinical Features Associated with Relapse in Early Stage EGFR-Mutated NSCLC: A Single Institution Knowledge Bank. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Tan A, Chua K, Teng Y, Takano A, Alvarez J, Nahar R, Rohatgi N, Lai G, Aung Z, Yeong J, Lim K, Naeini M, Kassam I, Jain A, Tan W, Gogna A, Too C, Kanesvaran R, Ng Q, Ang M, Rajasekaran T, Devanand A, Phua G, Tan B, Lee Y, Wang L, Teo A, Khng A, Lim M, Suteja L, Toh C, Lim W, Iyer N, Tam W, Tan E, Zhai W, Hillmer A, Skanderup A, Tan D. MA13.08 Genomic and Transcriptomic Features of Distinct Resistance Trajectories in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
34
|
Alvarez J, Chua K, Sim N, Abedi M, Chen J, Tan A, Lai G, Takano A, Lim W, Tan E, Lim K, Zhai W, Tan D, Skanderup A. P59.08 THOR: Multi-Ethnic, Open Access Thoracic Cancer Genomics Resource. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Lee J, Tan A, Zhou S, Liu S, Kim D, Masuda K, Batra U, Hayashi H, Goto Y, Tan S, Wu Y, Tan D, Ahn M. MA04.06 Clinical Characteristics and Outcomes in Advanced KRAS Mutant NSCLC – A Multi-Centre Collaboration in Asia (ATORG-005). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
36
|
Tan D, Farago A, Kummar S, Moreno V, Patel J, Lassen U, Solomon B, Rosen L, Leyvraz S, Reeves J, Brega N, Dima L, Childs B, Drilon A. MA11.09 Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.253] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
37
|
Abstract
Despite the amazing progress in the treatment of gastric cancer (GC), it is still the third leading cause of cancer death in the world. This study explored the key genes that are related to the prognosis and pathogenesis of GC. Data from the cancer genome atlas (TCGA) and Oncomine were applied to evaluate the expression of cystatin 2 (CST2) in GC samples. Kaplan-Meier plotter was carried out to detect the overall survival of GC patients with different expression levels of CST2. Gene Set Enrichment Analysis (GSEA) was carried out to investigate the functions and pathways connected with CST2 expression. Quantitative real-time polymerase chain reaction (qPCR) and Western blot assays were used to assess CST2 expression. The biological properties of GC cells were assessed with the support of cell proliferation and Transwell assays. Important proteins involved in the regulation of CST2 in GC cell behaviors were evaluated by Western blot. Through analysis of the database, we found that CST2 expression was significantly upregulated in GC samples and actively related to GC patients' poor outcomes. Importantly, the analysis of GSEA showed that GST2 expression was closely connected with the proliferation and migration of cells, as well as the TGF-β1 signaling pathway. In addition, biological assays illustrated that over-expression of CST2 strengthened the activity and metastasis of GC cells. After the upregulation of CST2, the expression of cyclin D1, N-cadherin, vimentin, TGF-β1, and Smad4 increased, and E-cadherin expression decreased. Our findings revealed that over-expression of CST2 enhanced the growth, migration, and invasion of GC cells through modulating the epithelial-mesenchymal transition (EMT) and TGF-β1 signaling pathway, affording a possible biomarker for the treatment of GC.
Collapse
Affiliation(s)
- W P Zhang
- Department of General Surgery, Ruijin Hospital/Lu Wan Branch, School of Medicine, Shanghai Jiaotong University, Shanghai, P. R. China
| | - Y Wang
- Department of General Surgery, Ruijin Hospital/Lu Wan Branch, School of Medicine, Shanghai Jiaotong University, Shanghai, P. R. China
| | - D Tan
- Department of General Surgery, Ruijin Hospital/Lu Wan Branch, School of Medicine, Shanghai Jiaotong University, Shanghai, P. R. China
| | - C G Xing
- Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, P. R. China
| |
Collapse
|
38
|
Tsoi K, Tan D, Stevenson J, Evans S, Jeys L, Botchu R. Indeterminate pulmonary nodules are not associated with worse overall survival in Ewing Sarcoma. J Clin Orthop Trauma 2021; 16:58-64. [PMID: 33717939 PMCID: PMC7920159 DOI: 10.1016/j.jcot.2020.12.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 10/26/2020] [Accepted: 12/16/2020] [Indexed: 11/26/2022] Open
Abstract
AIM Lung metastases are a negative prognostic factor in Ewing sarcoma, however, the incidence and significance of sub-centimetre pulmonary nodules at diagnosis is unclear. The aims of this study were to (1): determine the incidence of indeterminate pulmonary nodules (IPNs) in patients diagnosed with Ewing sarcoma (2); establish the impact of IPNs on overall and metastasis-free survival and (3) identify patient, oncological and radiological factors that correlate with poorer prognosis in patients that present with IPNs on their staging chest CT. MATERIALS & METHODS Between 2008 and 2016, 173 patients with a first presentation of Ewing sarcoma of bone were retrospectively identified from an institutional database. Staging and follow-up chest CTs for all patients with IPN were reviewed by a senior radiologist. Clinical and radiologic course were examined to determine overall- and metastasis-free survival for IPN patients and to identify demographic, oncological or nodule-specific features that predict which IPN represent true lung metastases. RESULTS Following radiologic re-review, IPN were found in 8.7% of patients. Overall survival for IPN patients was comparable to those with a normal staging chest CT (2-year overall survival of 73.3% [95% CI 43.6-89] and 89.4% [95% CI 81.6-94], respectively; p = 0.34) and was significantly better than for patients with clear metastases (46.0% [95% CI 31.9-59]; p < 0.0001). Similarly, there was no difference in metastasis-free survival between 'No Metastases' and 'IPN' patients (p = 0.16). Lung metastases developed in 40% of IPN patients at a median 9.6 months. Reduction of nodule size on neoadjuvant chemotherapy was associated with worse overall survival in IPN patients (p = 0.0084). CONCLUSION IPN are not uncommon in patients diagnosed with Ewing sarcoma. In this study, we were unable to detect a difference in overall- or metastasis-free survival between patients with IPN at diagnosis and patients with normal staging chest CTs.
Collapse
Affiliation(s)
- K.M. Tsoi
- Oncology Department, Royal Orthopaedic Hospital, Birmingham, UK
| | - D. Tan
- Oncology Department, Royal Orthopaedic Hospital, Birmingham, UK
| | - J. Stevenson
- Oncology Department, Royal Orthopaedic Hospital, Birmingham, UK,Aston University Medical School, Birmingham, UK
| | - S. Evans
- Oncology Department, Royal Orthopaedic Hospital, Birmingham, UK
| | - L.M. Jeys
- Oncology Department, Royal Orthopaedic Hospital, Birmingham, UK,Aston University Medical School, Birmingham, UK
| | - R. Botchu
- Department of Musculoskeletal Radiology, Royal Orthopaedic Hospital, Birmingham, UK,Corresponding author. Department of Musculoskeletal Radiology, The Royal Orthopedic Hospital, Bristol Road South, Northfield, Birmingham, UK.
| |
Collapse
|
39
|
Li Y, Du X, Liu S, Tan D, Li Z, Li L, Miao F. PNS14 Investigation of Physicians’ Digital Activities on Mitigating the IMPACT of Covid-19 in China. Value Health Reg Issues 2020. [PMCID: PMC7487513 DOI: 10.1016/j.vhri.2020.07.433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
40
|
Tan D. REVIEW CHAPTER ON IDEAL STUDENT LEADERSHIP AND THE IMPACT ON YOUTH DEVELOPMENT: LEADERSHIP AND PSYCHOLOGY FROM A PRACTITIONER’S PERSPECTIVE. Leadership 2020. [DOI: 10.1142/9789811213236_0014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- D. Tan
- Singapore Chinese Chamber of Commerce & Industry, Singapore
| |
Collapse
|
41
|
Naghiloo M, Tan D, Harrington PM, Alonso JJ, Lutz E, Romito A, Murch KW. Heat and Work Along Individual Trajectories of a Quantum Bit. Phys Rev Lett 2020; 124:110604. [PMID: 32242716 DOI: 10.1103/physrevlett.124.110604] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2019] [Accepted: 02/07/2020] [Indexed: 06/11/2023]
Abstract
We use a near quantum limited detector to experimentally track individual quantum state trajectories of a driven qubit formed by the hybridization of a waveguide cavity and a transmon circuit. For each measured quantum coherent trajectory, we separately identify energy changes of the qubit as heat and work, and verify the first law of thermodynamics for an open quantum system. We further establish the consistency of these results by comparison with the master equation approach and the two-projective-measurement scheme, both for open and closed dynamics, with the help of a quantum feedback loop that compensates for the exchanged heat and effectively isolates the qubit.
Collapse
Affiliation(s)
- M Naghiloo
- Department of Physics, Washington University, St. Louis, Missouri 63130, USA
| | - D Tan
- Department of Physics, Washington University, St. Louis, Missouri 63130, USA
- Shenzhen Institute for Quantum Science and Engineering and Department of Physics, Southern University of Science and Technology, Shenzhen 518055, People's Republic of China
| | - P M Harrington
- Department of Physics, Washington University, St. Louis, Missouri 63130, USA
| | - J J Alonso
- Department of Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - E Lutz
- Institute for Theoretical Physics I, University of Stuttgart, D-70550 Stuttgart, Germany
| | - A Romito
- Department of Physics, Lancaster University, Lancaster LA1 4YB, United Kingdom
| | - K W Murch
- Department of Physics, Washington University, St. Louis, Missouri 63130, USA
- Institute for Materials Science and Engineering, St. Louis, Missouri 63130, USA
| |
Collapse
|
42
|
Wu P, Xu R, Chen X, Zhao Y, Tan D, Zhao Y, Qin W, Zhang C, Ge X, Shi C. Establishment and characterization of patient-derived xenografts for hormone-naïve and castrate-resistant prostate cancers to improve treatment modality evaluation. Aging (Albany NY) 2020; 12:3848-3861. [PMID: 32092044 PMCID: PMC7066917 DOI: 10.18632/aging.102854] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2019] [Accepted: 01/28/2020] [Indexed: 04/12/2023]
Abstract
Prostate cancer (PC) is a heterogeneous disease characterized by variable morphological patterns. Thus, establishing a patient-derived xenograft (PDX) model that retains the key features of the primary tumor for each type of PC is important for appropriate evaluation. In this study, we established PDX models of hormone-naïve (D17225) and castration-resistant (B45354) PC by implanting fresh tumor samples, obtained from patients with advanced PC under the renal capsule of immune-compromised mice. Supplementation with exogenous androgens shortened the latent period of tumorigenesis and increased the tumor formation rate. The PDX models exhibited the same major genomic and phenotypic features of the disease in humans and maintained the main pathological features of the primary tumors. Moreover, both PDX models showed different outcomes after castration or docetaxel treatment. The hormone-naïve D17225 PDX model displayed a range of responses from complete tumor regression to overt tumor progression, and the development of castrate-resistant PC was induced after castration. The responses of the two PDX models to androgen deprivation and docetaxel were similar to those observed in patients with advanced PC. These new preclinical PC models will facilitate research on the mechanisms underlying treatment response and resistance.
Collapse
Affiliation(s)
- Pengpeng Wu
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China
| | - Rong Xu
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China
| | - Xue Chen
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China
| | - Ya Zhao
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China
- Biomedicine Application Laboratory, School of Life Science and Technology, Xidian University, Xi’an, Shaanxi 710071, China
| | - Dengxu Tan
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China
| | - Yong Zhao
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China
| | - Weijun Qin
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, China
| | - Caiqin Zhang
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China
| | - Xu Ge
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China
| | - Changhong Shi
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China
| |
Collapse
|
43
|
Zhao Y, Zhang H, Wu P, Tan D, Zhao Y, Zhang C, Wang J, Bai B, An J, Shi C. Mediated Imaging and Improved Targeting of Farnesylthiosalicylic Acid Delivery for Pancreatic Cancer via Conjugation with Near-Infrared Fluorescence Heptamethine Carbocyanine Dye. ACS Appl Bio Mater 2020; 3:1129-1138. [DOI: 10.1021/acsabm.9b01068] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
- Ya Zhao
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an 710032, China
| | - He Zhang
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an 710032, China
| | - Pengpeng Wu
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an 710032, China
| | - Dengxu Tan
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an 710032, China
| | - Yong Zhao
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an 710032, China
| | - Caiqin Zhang
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an 710032, China
| | - Jie Wang
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an 710032, China
| | - Bing Bai
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an 710032, China
| | - Jiaze An
- Department of Hepatobiliary and Pancreaticosplenic Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an 710069, China
| | - Changhong Shi
- Division of Cancer Biology, Laboratory Animal Center, The Fourth Military Medical University, Xi’an 710032, China
| |
Collapse
|
44
|
Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T, Dingemans AM, Liu SV, Peled N, Pennell NA, Reck M, Rolfo C, Tan D, Vansteenkiste J, West H, Besse B. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration. Ann Oncol 2019; 30:1686-1688. [PMID: 31504132 DOI: 10.1093/annonc/mdz295] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- G Mountzios
- Department of Medical Oncology, Henry Dunant Hospital Center, Athens, Greece.
| | - J Remon
- Department of Medical Oncology, CIOCC HM Delfos Hospital, Barcelona, Spain
| | - S Novello
- Department of Oncology, University of Turin, AOU San Luigi, Orbassano, Italy
| | - N Blais
- Centre Hospitalier Universitaire de Montréal, University of Montreal, Montreal, Canada
| | - R Califano
- Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester; Division of Cancer Sciences, University of Manchester, Manchester, UK
| | - T Cufer
- University Clinic Golnik, Medical Faculty Ljubljana, Slovenia
| | - A M Dingemans
- Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht and Erasmus Medical Center, Rotterdam, The Netherlands
| | - S V Liu
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
| | - N Peled
- Soroka Medical Center and Ben-Gurion University, Beer-Sheva, Israel
| | - N A Pennell
- Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, USA
| | - M Reck
- Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany
| | - C Rolfo
- Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, USA
| | - D Tan
- Division of Medical Oncology, National Cancer Centre, Singapore
| | - J Vansteenkiste
- Respiratory Oncology Unit, University Hospital KU Leuven, Leuven, Belgium
| | - H West
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, USA
| | - B Besse
- Cancer Medicine Department, Institut Gustave Roussy, Villejuif; Université Paris-Saclay, Orsay, France
| |
Collapse
|
45
|
Gutierrez M, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Lam W, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. P1.01-107 KEYNOTE-495/KeyImPaCT: Phase 2 Biomarker-Directed Study of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.822] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
46
|
Tan A, Chua K, Takano A, Alvarez J, Ong B, Koh T, Aung Z, Jain A, Lai G, Tan W, Ang M, Ng Q, Kanesvaran R, Rajasekaran T, Iyer N, Lim W, Zhai W, Toh C, Skanderup A, Tan E, Tan D. P1.17-07 Neoadjuvant Gefitinib in Resectable Early Stage EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): A Window-of-Opportunity Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1281] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
47
|
Tan A, Lai G, Tan G, Poon S, Doble B, Lim T, Aung Z, Takano A, Tan W, Ang M, Tan B, Devanand A, Too C, Gogna A, Ong B, Koh T, Kanesvaran R, Ng Q, Jain A, Rajasekaran T, Lim A, Lim W, Toh C, Tan E, Lim K, Tan D. P1.09-19 High-Throughput Next Generation Sequencing of Treatment-Naïve Non-Squamous NSCLC: The Singapore National Lung Profiling Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
48
|
Tan A, Mok T, Kim D, Yang J, Lee C, Soo R, Reungwetwattana T, Tan D, Loong H. P2.14-20 ATORG-003: Dacomitinib With or Without Dose Titration as First-Line Therapy for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1805] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
49
|
|
50
|
Abstract
Prostate cancer (Pca) is a heterogeneous disease with multiple morphological patterns. Thus, the establishment of a patient-derived xenograft (PDX) model that retains key features of the primary tumor is of great significance. This review demonstrates the characteristics and advantages of the Pca PDX model and summarizes the main factors affecting the establishment of the model. Because this model well recapitulates the diverse heterogeneity observed in the clinic, it was extensively utilized to discover new therapeutic targets, screen drugs, and explore metastatic mechanisms. In the future, clinical phenotype and different stages of the Pca patient might be faithfully reflected by PDX model, which provides tremendous potential for understanding Pca biology and achieving individualized treatment.
Collapse
Affiliation(s)
- Changhong Shi
- Division of Cancer Biology, Laboratory Animal Center, the Fourth Military Medical University, Xi'an 710032, China.,School of Basic Medical Sciences, the Chengdu Medical University, Xindu 610500, China
| | - Xue Chen
- Division of Cancer Biology, Laboratory Animal Center, the Fourth Military Medical University, Xi'an 710032, China.,School of Basic Medical Sciences, the Chengdu Medical University, Xindu 610500, China
| | - Dengxu Tan
- Division of Cancer Biology, Laboratory Animal Center, the Fourth Military Medical University, Xi'an 710032, China
| |
Collapse
|